Effect of the Purinergic Inhibitor Oxidized ATP in a Model of Islet Allograft Rejection
Overview
Authors
Affiliations
The lymphocytic ionotropic purinergic P2X receptors (P2X1R-P2X7R, or P2XRs) sense ATP released during cell damage-activation, thus regulating T-cell activation. We aim to define the role of P2XRs during islet allograft rejection and to establish a novel anti-P2XRs strategy to achieve long-term islet allograft function. Our data demonstrate that P2X1R and P2X7R are induced in islet allograft-infiltrating cells, that only P2X7R is increasingly expressed during alloimmune response, and that P2X1R is augmented in both allogeneic and syngeneic transplantation. In vivo short-term P2X7R targeting (using periodate-oxidized ATP [oATP]) delays islet allograft rejection, reduces the frequency of Th1/Th17 cells, and induces hyporesponsiveness toward donor antigens. oATP-treated mice displayed preserved islet grafts with reduced Th1 transcripts. P2X7R targeting and rapamycin synergized in inducing long-term islet function in 80% of transplanted mice and resulted in reshaping of the recipient immune system. In vitro P2X7R targeting using oATP reduced T-cell activation and diminished Th1/Th17 cytokine production. Peripheral blood mononuclear cells obtained from long-term islet-transplanted patients showed an increased percentage of P2X7R⁺CD4⁺ T cells compared with controls. The beneficial effects of oATP treatment revealed a role for the purinergic system in islet allograft rejection, and the targeting of P2X7R is a novel strategy to induce long-term islet allograft function.
Diabetes current and future translatable therapies.
Gonzalez-Sanchez F, Sanchez-Huerta T, Huerta-Gonzalez A, Sepulveda-Villegas M, Altamirano J, Aguilar-Aleman J Endocrine. 2024; 86(3):865-881.
PMID: 38971945 DOI: 10.1007/s12020-024-03944-8.
Sterile inflammation in liver transplantation.
Kahan R, Cray P, Abraham N, Gao Q, Hartwig M, Pollara J Front Med (Lausanne). 2023; 10:1223224.
PMID: 37636574 PMC: 10449546. DOI: 10.3389/fmed.2023.1223224.
Reversal of Experimental Autoimmune Diabetes With an sCD39/Anti-CD3 Treatment.
Fotino C, Molano R, Ben Nasr M, Umland O, Fraker C, Ulissi U Diabetes. 2023; 72(11):1641-1651.
PMID: 37625134 PMC: 10588287. DOI: 10.2337/db23-0178.
Mesto N, Movassat J, Tourrel-Cuzin C Front Endocrinol (Lausanne). 2023; 13:1099152.
PMID: 37065173 PMC: 10099247. DOI: 10.3389/fendo.2022.1099152.
P2 Receptors: Novel Disease Markers and Metabolic Checkpoints in Immune Cells.
Vultaggio-Poma V, Di Virgilio F Biomolecules. 2022; 12(7).
PMID: 35883539 PMC: 9313346. DOI: 10.3390/biom12070983.